0.7027

7.61% -0.0537

Outlook Therapeutics Inc (OTLK)

Overview News Price History Financials Discussions Forecast Stock Split

Outlook Therapeutics Inc stock is traded at $0.7027, with a volume of 68.66M. It is down -7.61% in the last 24 hours and down -49.72% over the past month. Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Previous Close:

$0.7564

Open:

$0.7954

24h Volume:

68.66M

Relative Volume:

2.81

Market Cap:

$131.42M

Revenue:

$424.90K

Net Income/Loss:

$-94.02M

P/E Ratio:

-0.2829

EPS:

-2.4842

Net Cash Flow:

$-51.25M

1W Performance:

-39.23%

1M Performance:

-49.72%

6M Performance:

+65.49%

1Y Performance:

-70.13%

1-Day Range:

$0.685

$0.7975

1-Week Range:

$0.685

$1.18

52-Week Range:

$0.1611

$3.39

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name

Outlook Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(609) 619-3990

Address

111 S. WOOD AVENUE, ISELIN, NJ

Employee

Twitter

Next Earnings Date

2026-08-14

Latest SEC Filings

OTLK's Discussions on Twitter

Compare OTLK vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OTLK Outlook Therapeutics Inc	0.7028	141.44M	424.90K	-94.02M	-51.25M	-2.4842
VRTX Vertex Pharmaceuticals Inc	515.67	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.59	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	993.07	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.47	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.63	39.31B	5.76B	514.49M	1.10B	4.4813

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-28-25	Downgrade	Guggenheim	Buy → Neutral
Dec-02-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Mar-27-24	Upgrade	BTIG Research	Neutral → Buy
Feb-15-24	Upgrade	Chardan Capital Markets	Neutral → Buy
Jan-25-24	Upgrade	Guggenheim	Neutral → Buy
Dec-27-23	Upgrade	CapitalOne	Equal Weight → Overweight
Aug-31-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-31-23	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-30-23	Downgrade	BTIG Research	Buy → Neutral
Aug-30-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Aug-30-23	Downgrade	CapitalOne	Overweight → Equal Weight
Aug-30-23	Downgrade	Guggenheim	Buy → Neutral
Jul-13-23	Initiated	CapitalOne	Overweight
Apr-03-23	Initiated	Guggenheim	Buy
Feb-06-23	Initiated	Cantor Fitzgerald	Overweight
Oct-31-22	Initiated	BTIG Research	Buy
Sep-13-22	Initiated	Chardan Capital Markets	Buy
Sep-11-19	Initiated	Ladenburg Thalmann	Buy
May-16-19	Initiated	Oppenheimer	Outperform
Apr-22-19	Initiated	Ascendiant Capital Markets	Buy

View All

Outlook Therapeutics Inc Stock (OTLK) Latest News

10:00 AM

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp - Yahoo Finance

10:00 AM

06:28 AM

Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing - Moomoo

06:28 AM

12:21 PM

Outlook Therapeutics Posts Q3 Financials, Raises Funds for Lytenava Launch - VisionMonday.com

12:21 PM

Aug 16, 2026

OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits

Aug 15, 2026

Outlook Therapeutics CEO Robert Jahr acquires shares and warrants for $0 - Investing.com South Africa